POSTER 070 Effect of elinzanetant for the treatment of vasomotor symptoms associated with menopause across race and ethnicity subgroups: pooled data from two Phase 3 studies



JoAnn V. Pinkerton¹, James A. Simon², Hadine Joffe³, Pauline M. Maki⁴, Rossella E. Nappi⁵, Nick Panay⁶, Claudio N. Soares⁷, Rebecca C. Thurston⁸, Chenshuang Lu⁹, Cecilia Caetano¹⁰, Claudia Haberland¹¹, Lineke Zuurman¹⁰

¹University of Virginia, Charlottesville, VA, USA; ²George Washington University, IntimMedicine Specialists, Washington, DC, USA; ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ⁴University of Illinois, Chicago, IL, USA; ⁵University of Pavia, Pavia, Italy; ⁶Queen Charlotte's & Chelsea Hospital, Imperial College, London, UK; ⁷Queen's University School of Medicine, Kingston, Ontario, Canada; ⁸University of Pittsburgh, Pittsburgh, PA, USA; ⁹Bayer U.S. LLC, USA; ¹⁰Bayer CC AG, Basel, Switzerland; ¹¹Bayer AG, Berlin, Germany




In the pivotal randomized Phase 3 trials, OASIS 1 and 2, elinzanetant (EZN), a dual neurokinin-1 and -3 receptor antagonist, significantly reduced the frequency and severity of menopausal vasomotor symptoms (VMS; also known as hot flashes) compared with placebo (PBO).¹ It is important to understand the efficacy of EZN across race and ethnicity. Therefore, this analysis aimed to evaluate the efficacy of EZN in pre-specified race and ethnicity subgroups using pooled data from the OASIS 1 and 2 trials.

METHODS

Participants and interventions

Naturally/surgically postmenopausal women aged 40–65 years with ≥50 moderate-to-severe VMS episodes/week were randomized 1:1 to receive EZN 120 mg for 26 weeks or PBO for 12 weeks followed by EZN for 14 weeks.



Main outcome measures

Participants were evaluated by:

Race:

Black/African American

» White

Ethnicity:


>>> Hispanic/Latino

» Not Hispanic/Latino

Data were pooled from OASIS 1 and 2 trials. Other subgroups were not included in the analysis due to small sample size. Mean changes in daily moderate-to-severe VMS frequency from baseline to week 12 as well as the interaction between subgroup and treatment were analyzed by a mixed model with repeated measures. All p-values were nominal and one-sided (α level of 0.025).



Figure 1. LS mean change from baseline to week 12 in average daily moderate-to-severe VMS frequency



At baseline, there was some variation in mean daily VMS frequency across Black/African American, White, Hispanic/Latino and Not Hispanic/Latino subgroups (Table 2).

- Mean (SD) reductions from baseline to week 12 in daily VMS frequency were numerically greater with EZN than with PBO across Black/African American, White, and non-Hispanic/Latino subgroups (Figure 1); differences were nominally significant for White and non-Hispanic/Latino subgroups.
- In the Hispanic/Latino subgroup, larger mean reductions in VMS frequency from baseline to week 12 were seen in the PBO group, which were numerically greater than with EZN, but differences did not reach statistical significance (Figure 1).
- The differences in least square (LS) means between EZN and PBO were not nominally significantly different between White and Black/African American subgroups or between Hispanic/Latino and non-Hispanic/Latino subgroups.

Table 1. Participant race and ethnicity^a

	EZN 120 mg (n=399)	PBO (n=397)					
Race, n (%)							
White	314 (78.7%)	326 (82.1%)					
Black or African American	73 (18.3%)	63 (15.9%)					
Ethnicity, n (%)							
Not Hispanic or Latino	366 (91.7%)	354 (89.2%)					
Hispanic or Latino	30 (7.5%)	38 (9.6%)					

n = number of subjects with observed value for this timepoint.

Table 2. Average daily moderate-to-severe VMS frequency by race and ethnicity

	Black or African American		White		Hispanic or Latino		Not Hispanic or Latino	
	EZN 120 mg (n=73)	PBO (n=63)	EZN 120 mg (n=314)	PBO (n=326)	EZN 120 mg (n=30)	PBO (n=38)	EZN 120 mg (n=366)	PBO (n=354)
Baseline, mean (SD)	16.6 (16.1)	19.1 (23.0)	13.4 (6.5)	14.6 (9.4)	1 <i>5</i> .5 (8.5)	22.6 (17.7)	13.9 (9.2)	14.4 (11.7)
LS mean change from baseline to week 12 (SE)	-11.5 (2.8)	-7.7 (2.9)	-9.1 (0.3)	-5.9 (0.3)	-8.9 (3.1)	-9.0 (2.9)	-9.2 (0.4)	-5.9 (0.4)
Difference in LS means (SE) [95% CI] p-value (one- sided)	-3.9 (2.2) [-8.2, 0.5] p=0.0414		-3.2 (0.5) [-4.1, -2.2] p<0.0001		0.1 (2.4) [-4.5, 4.7] p=0.5156		-3.3 (0.6) [-4.4, -2.2] p<0.0001	



EZN was consistently efficacious in reducing moderate-to-severe VMS frequency across Black/African American, White, and non-Hispanic/Latino postmenopausal women

VMS can vary across race and ethnicity; therefore, it is important to understand the efficacy of VMS treatments across these groups Reductions in VMS frequency with EZN were nominally significantly greater than with PBO for White and non-Hispanic/Latino subgroups A larger PBO response was observed in the Hispanic/Latino subgroup; small group numbers and large relative baseline differences in VMS frequency may limit the generalizability of these findings

ACKNOWLEDGEMENTS

This study was sponsored by Bayer. Medical writing assistance was provided by Emma Case of Highfield, Oxford, UK, funded by Bayer.



Pinkerton JV, et al. JAMA 2024. doi:10.1001/jama.2024.14618.

DISCLOSURES

Solarn Pinkerton was principal investigator on the OASIS 2 clinical trial, fees to the University of Virginia and has been a consultant with Bayer HealthCare Pharmaceuticals and Pfizer. James Simon was principal investigator on the OASIS 1 trial; has grant/research support from: AbbVie, Inc., Bayer HealthCare LLC., Daré Bioscience, Ipsen, Mylan/Viatris Inc., Myovant Sciences, ObsEva SA, Sebela Pharmaceuticals Inc., Viveve Medical; has been a consultant/advisory boards of: Bayer HealthCare Pharmaceuticals Inc., Besins HealthCare, California Institute of Integral Studies (CIIS), Camargo Pharmaceutical Services, LLC, Covance Inc., Daré Bioscience, DEKA M.E.LA S.r.l., Femasys Inc., KaNDy/NeRRe Therapeutics Ltd., Khyria, Madorra Pty Ltd., Mitsubishi Tanabe Pharma Development America, Inc., QUE Oncology Pty, Limited, Scynexis Inc., Sebela Pharmaceuticals, Inc., Sprout Pharmaceuticals, Inc., Vella Bioscience Inc.; has served on the Speaker's bureaus of: Mayne Pharma, Inc., Myovant Sciences, Inc., Pfizer Inc., Pharmavite LLC., Scynexis Inc., Therapeutics.MD; and is a stockholder (direct purchase) in: Sermonix Pharmaceuticals. Hadine Joffe has received grants from: NIH, Merck, Pfizer and has performed consultancy work for: Abbott, Astellas, Bayer HealthCare AG, and Pfizer and received speakling honorarium from: Mithra, equity in Alloy, MidiHealth, and Estrigenix. Rossella E. Nappi had past financial relationships (lecturer, member of advisory boards and/or consultant) with Boehringer Ingelheim, Ely Lilly, Endoceutics, Palatin Technologies, Pfizer Inc., Procter & Gonable Co, Novo Nordisk, Organon & Co, Shionogi Limited, Theramex, Viatris, and Vichy Laboratories. Nick Panay has lectured and acted in an advisory capacity for: Abbott, Astellas, Bayer, HealthCare AG, Besins HealthCare AG, Besins HealthCare, Exeltis, Fidia, Gedeon Richter, HRA Pharma, Merck & Co, Novo Nordisk, Organon & Co, Shionogi Limited, Theramex, Viatris, and Vichy Laboratories. Nick Panay has lectured and acted in an advisory capacity for: Abbott, Astel